Cargando…
Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age
BACKGROUND: Since it was first identified in early November 2021, the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread quickly and replaced the B.1.617.2 (delta) variant as the dominant variant in many countries. Data on the real-world effectiven...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Massachusetts Medical Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342421/ https://www.ncbi.nlm.nih.gov/pubmed/35857701 http://dx.doi.org/10.1056/NEJMoa2203209 |
_version_ | 1784760822629662720 |
---|---|
author | Tan, Sharon H.X. Cook, Alex R. Heng, Derrick Ong, Benjamin Lye, David C. Tan, Kelvin B. |
author_facet | Tan, Sharon H.X. Cook, Alex R. Heng, Derrick Ong, Benjamin Lye, David C. Tan, Kelvin B. |
author_sort | Tan, Sharon H.X. |
collection | PubMed |
description | BACKGROUND: Since it was first identified in early November 2021, the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread quickly and replaced the B.1.617.2 (delta) variant as the dominant variant in many countries. Data on the real-world effectiveness of vaccines against the omicron variant in children are lacking. METHODS: In a study conducted from January 21, 2022, through April 8, 2022, when the omicron variant was spreading rapidly, we analyzed data on children in Singapore who were 5 to 11 years of age. We assessed the incidences of all reported SARS-CoV-2 infections (confirmed on polymerase-chain-reaction [PCR] assay, rapid antigen testing, or both), SARS-CoV-2 infections confirmed on PCR assay, and coronavirus disease 2019 (Covid-19)–related hospitalizations among unvaccinated, partially vaccinated (≥1 day after the first dose of vaccine and up to 6 days after the second dose), and fully vaccinated children (≥7 days after the second dose). Poisson regression was used to estimate vaccine effectiveness from the incidence rate ratio of outcomes. RESULTS: A total of 255,936 children were included in the analysis. Among unvaccinated children, the crude incidence rates of all reported SARS-CoV-2 infections, PCR-confirmed SARS-CoV-2 infections, and Covid-19–related hospitalizations were 3303.5, 473.8, and 30.0 per 1 million person-days, respectively. Among partially vaccinated children, vaccine effectiveness was 13.6% (95% confidence interval [CI], 11.7 to 15.5) against all SARS-CoV-2 infections, 24.3% (95% CI, 19.5 to 28.9) against PCR-confirmed SARS-CoV-2 infection, and 42.3% (95% CI, 24.9 to 55.7) against Covid-19–related hospitalization; in fully vaccinated children, vaccine effectiveness was 36.8% (95% CI, 35.3 to 38.2), 65.3% (95% CI, 62.0 to 68.3), and 82.7% (95% CI, 74.8 to 88.2), respectively. CONCLUSIONS: During a period when the omicron variant was predominant, BNT162b2 vaccination reduced the risks of SARS-CoV-2 infection and Covid-19–related hospitalization among children 5 to 11 years of age. |
format | Online Article Text |
id | pubmed-9342421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Massachusetts Medical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-93424212022-08-01 Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age Tan, Sharon H.X. Cook, Alex R. Heng, Derrick Ong, Benjamin Lye, David C. Tan, Kelvin B. N Engl J Med Original Article BACKGROUND: Since it was first identified in early November 2021, the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread quickly and replaced the B.1.617.2 (delta) variant as the dominant variant in many countries. Data on the real-world effectiveness of vaccines against the omicron variant in children are lacking. METHODS: In a study conducted from January 21, 2022, through April 8, 2022, when the omicron variant was spreading rapidly, we analyzed data on children in Singapore who were 5 to 11 years of age. We assessed the incidences of all reported SARS-CoV-2 infections (confirmed on polymerase-chain-reaction [PCR] assay, rapid antigen testing, or both), SARS-CoV-2 infections confirmed on PCR assay, and coronavirus disease 2019 (Covid-19)–related hospitalizations among unvaccinated, partially vaccinated (≥1 day after the first dose of vaccine and up to 6 days after the second dose), and fully vaccinated children (≥7 days after the second dose). Poisson regression was used to estimate vaccine effectiveness from the incidence rate ratio of outcomes. RESULTS: A total of 255,936 children were included in the analysis. Among unvaccinated children, the crude incidence rates of all reported SARS-CoV-2 infections, PCR-confirmed SARS-CoV-2 infections, and Covid-19–related hospitalizations were 3303.5, 473.8, and 30.0 per 1 million person-days, respectively. Among partially vaccinated children, vaccine effectiveness was 13.6% (95% confidence interval [CI], 11.7 to 15.5) against all SARS-CoV-2 infections, 24.3% (95% CI, 19.5 to 28.9) against PCR-confirmed SARS-CoV-2 infection, and 42.3% (95% CI, 24.9 to 55.7) against Covid-19–related hospitalization; in fully vaccinated children, vaccine effectiveness was 36.8% (95% CI, 35.3 to 38.2), 65.3% (95% CI, 62.0 to 68.3), and 82.7% (95% CI, 74.8 to 88.2), respectively. CONCLUSIONS: During a period when the omicron variant was predominant, BNT162b2 vaccination reduced the risks of SARS-CoV-2 infection and Covid-19–related hospitalization among children 5 to 11 years of age. Massachusetts Medical Society 2022-07-20 /pmc/articles/PMC9342421/ /pubmed/35857701 http://dx.doi.org/10.1056/NEJMoa2203209 Text en Copyright © 2022 Massachusetts Medical Society. All rights reserved. This article is made available via the PMC Open Access Subset for unrestricted re-use, except commercial resale, and analyses in any form or by any means with acknowledgment of the original source. PMC is granted a license to make this article available via PMC and Europe PMC, subject to existing copyright protections. |
spellingShingle | Original Article Tan, Sharon H.X. Cook, Alex R. Heng, Derrick Ong, Benjamin Lye, David C. Tan, Kelvin B. Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age |
title | Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age |
title_full | Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age |
title_fullStr | Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age |
title_full_unstemmed | Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age |
title_short | Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age |
title_sort | effectiveness of bnt162b2 vaccine against omicron in children 5 to 11 years of age |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342421/ https://www.ncbi.nlm.nih.gov/pubmed/35857701 http://dx.doi.org/10.1056/NEJMoa2203209 |
work_keys_str_mv | AT tansharonhx effectivenessofbnt162b2vaccineagainstomicroninchildren5to11yearsofage AT cookalexr effectivenessofbnt162b2vaccineagainstomicroninchildren5to11yearsofage AT hengderrick effectivenessofbnt162b2vaccineagainstomicroninchildren5to11yearsofage AT ongbenjamin effectivenessofbnt162b2vaccineagainstomicroninchildren5to11yearsofage AT lyedavidc effectivenessofbnt162b2vaccineagainstomicroninchildren5to11yearsofage AT tankelvinb effectivenessofbnt162b2vaccineagainstomicroninchildren5to11yearsofage |